CClinicalTrials.gg
Not yet recruitingNCT07117929Updated Aug 12, 2025

Effects of Pulsed Electromagnetic Field Therapy on Meniscal Healing, Symptom Relief, and Knee Function

An interventional study of Active PEMF and Sham PEMF in Meniscal Tears, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if pulsed electromagnetic field (PEMF) combined with home exercise improves healing and function in adults with meniscus tears. The main questions it aims to answer are:

  1. Does PEMF therapy help heal meniscus tears, as seen on MRI scans?
  2. Does PEMF therapy subjectively reduce knee pain, improve movement, and enhance quality of life?
  3. Does PEMF therapy objectively help patients perform daily activities more easily?

Researchers will compare PEMF therapy against a sham (inactive) treatment to determine if it provides additional benefits.

Participants will:

  • Be assigned randomly to either the PEMF group (active treatment) or the sham PEMF group (inactive, but identical in appearance)
  • Receive either real PEMF therapy or sham treatment twice a week for 8 weeks (each session lasts 10 minutes).
  • Follow a standard home exercise program to strengthen their knees.
  • Have their knee function, pain levels, and healing progress checked through MRI scans, questionnaires, imaging and physical tests.
  • Return for 3 follow-up visits after the 8-week treatment period.
02

Conditions studied

  • Meniscal Tears

Keywords

  • meniscal injuries
  • meniscus tear
  • meniscal injury
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female patients aged 18-60
  • Clinical history, signs, and symptoms indicative of a meniscal tear
  • MRI confirmation of a non-displaced, and unilateral meniscal tear
  • Meniscal tears located within red-white and white-white zones
  • Willingness to adhere to a 8-week regimen of PEMF and exercise therapy
  • Ability to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Congenital discoid meniscus confirmed by MRI
  • Complex, oblique, flap, or displaced bucket handle tears confirmed by MRI
  • Meniscal root tears confirmed by MRI
  • Evidence of partial healing on baseline MRI
  • Presence of mechanical symptoms (e.g., locking or catching)
  • Acute onset exacerbation of knee symptoms (e.g., severe pain or swelling)
  • Surgical intervention during the therapy session
  • Knee axis deformities that necessitate surgical correction
  • Prior surgery or fracture in the affected limb within the past 12 months
  • Severe radiographic knee OA (Kellgren-Lawrence scale ≥2)
  • Implanted electronic medical devices (e.g., pacemakers or cochlear implants) • Current pregnancy or intention to become pregnant during the study period
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    PEMF Group

    1. PEMF Therapy: Participants will undergo active PEMF therapy sessions lasting 10 minutes each, conducted twice weekly for 16 sessions, with a specified PEMF device (QuantumTX Pte Ltd, Singapore). 2. Exercise Therapy: All participants will be provided with the same standardised home exercise protocol.

    Device: Active PEMF · Other: Exercise

  • Sham comparator
    Control Group

    1. Sham PEMF Therapy: Participants will undergo sham PEMF therapy sessions lasting 10 minutes each, conducted twice weekly for 16 sessions, with a specified PEMF device (QuantumTX Pte Ltd, Singapore). 2. Exercise Therapy: All participants will be provided with the same standardised home exercise protocol.

    Device: Sham PEMF · Other: Exercise

Interventions

  • DeviceActive PEMF

    PEMF: 1.5mT, 10Hz, 10 minutes

  • DeviceSham PEMF

    PEMF 0mT, 0Hz, 10 minutes

  • OtherExercise

    Standardised home exercise protocol

06

What researchers measure

Primary outcomes

  1. Between-group difference in mean change of intrameniscal fluid-equivalent signal area at 6 months post-intervention, as assessed by MRI.

    A musculoskeletal radiologist, blinded to the participants' group assignments and clinical details, will perform these assessments using fat- suppressed T2-weighted imaging. The primary imaging endpoint will be the between-group difference in the mean change of the intrameniscal fluid-equivalent signal area (mm2) from baseline to 6 months. The fluid-equivalent signal area will be delineated and quantified using standardized region-of-interest (ROI) methods on consecutive slices encompassing the original tear site.

    Time frame: Baseline to 6 months post intervention

Secondary outcomes

  1. Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Scores for Pain, Symptoms, Activities of Daily Living, Sport/Recreation Function, and Knee-Related Quality of Life

    The KOOS score is a 42-item patient-reported outcome measure assessing five subscales: Pain (9 items, score range 0-100), Symptoms (7 items, 0-100), Activities of Daily Living (17 items, 0-100), Sport/Recreation Function (5 items, 0-100), and Quality of Life (4 items, 0-100). Each subscale is scored separately from 0 (extreme problems) to 100 (no problems), with higher scores indicating better outcomes.

    Time frame: Baseline to 1-, 2-, 6-, and 12-months post intervention

  2. Change in Western Ontario Meniscal Evaluation Tool (WOMET) Scores for Physical Symptoms, Sports/Work/Lifestyle, and Emotional Domains

    The WOMET is a 16-item patient-reported questionnaire assessing meniscal tear-related quality of life across three domains: Physical Symptoms (10 items), Sports/Recreation/Work/Lifestyle (4 items), and Emotions (2 items). Each item is scored from 0 (no problem) to 5 (extreme problem), with total scores transformed to a 0-100 scale where 0 represents the best possible status and 100 represents the worst possible status. Higher scores indicate worse outcomes.

    Time frame: Baseline, 1, 2, 6, and 12 months post-intervention

  3. Change from Baseline in Active Knee Range of Motion at 12 Month

    Participant-initiated knee flexion-extension range measured in degrees using standardized goniometry, recording movement from full extension to maximum voluntary flexion.

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post commencement of intervention.

  4. Change from Baseline in Passive Knee Range of Motion at 12 Month

    Researcher-assisted knee flexion-extension range measured in degrees using standardized goniometry, recording movement from full extension to maximum assisted flexion without participants' muscle activation

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post commencement of intervention

  5. Change from Baseline in 60-Second Sit-to-Stand Test Score (Number of Repetitions) at 12 Months

    Quantifies lower limb functional strength and endurance by counting the maximum number of full sit-to-stand cycles completed in 60 seconds from a standardized-height chair. Higher counts indicate better functional performance.

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post commencement of intervention.

  6. Change from Baseline in 30-Second Step-Up Test Score (Number of Repetitions) at 12 Months

    The maximum number of complete step-up cycles performed in 30 seconds on a standardized step. Higher counts indicate better unilateral strength.

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post intervention

  7. Change from Baseline in 30-Second Step-Down Test Score (Number of Repetitions) at 12 Months

    Quantifies unilateral lower limb strength by counting the maximum number of complete step-down cycles performed in 30 seconds on a standardized step. Higher counts indicate better unilateral strength and eccentric control.

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post commencement of intervention

  8. Change from Baseline in Tissue Oxygenation 8 Weeks Using Photoacoustic Ultrasound Imaging

    Oxygenation saturation levels (%) measured by photoacoustic ultrasound around the meniscal tissue area.

    Time frame: Weekly during the 8-week intervention

  9. Change from Baseline Vascularity Levels at 8 weeks using Photoacoustic Ultrasound Imaging.

    Vascularity levels (AU) measured by photoacoustic ultrasound around the meniscal tissue area.

    Time frame: Weekly during the 8-week intervention

  10. Change from baseline skin temperature around the knee joint at 8 weeks using infrared thermography imaging.

    Time frame: Weekly during the 8-week intervention

  11. Change from Baseline in Meniscal Morphology at 8 Weeks Using Ultrasound Imaging

    Meniscal structural integrity assessed via standardized ultrasound protocol using a validated 4-point scale where higher grades indicate worse pathology.

    Time frame: Baseline and weekly during the 8-week intervention

  12. Number of participants with re-injury and associated ligament injuries, as assessed via both clinical examination and MRI.

    A re-injury or new ligament injury will be confirmed if both clinical examination indicates instability or significant changes from baseline, and MRI shows new or worsened structural damage compared to baseline images. We will document all instances of re-injury or new ligament injuries, including their nature and severity. The incidence of re-injuries and new ligament injuries will be compared between the PEMF and control groups, and we will analyze any correlation between meniscal healing status and the occurrence of re-injuries.

    Time frame: Baseline to 6 months post commencement of intervention

  13. Change in Static Postural Control Assessed by Zebris Stance Analysis

    Quantitative postural control assessment during 10-second standing on the Zebris stance analysis system, which consists of a capacitance-based foot pressure platform inserted within a treadmill. Parameters include postural sway and weight distribution such as sway area, forefoot vs heel force ratio, left vs right symmetry

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post intervention

  14. Change in Gait Function Assessed by Zebris Gait Analysis

    Quantitative gait analysis during 5-minute walking on the Zebris gait analysis system, which consists of a capacitance-based foot pressure platform inserted within a treadmill. Spatiotemporal parameters (gait speed, step length, stride length, cadence), dynamic balance (centre of pressure path length, lateral symmetry index), and load distribution metrics (peak heel/forefoot pressure, weight transfer timing) will be collected.

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post intervention

  15. Change in Running Function Assessed by Zebris Gait Analysis

    Quantitative gait analysis during a 5-minute run on the Zebris gait analysis system, which consists of a capacitance-based foot pressure platform inserted within a treadmill. Spatiotemporal parameters (gait speed, step length, stride length, cadence), dynamic balance (centre of pressure path length, lateral symmetry index), and load distribution metrics (peak heel/forefoot pressure, weight transfer timing) will be collected.

    Time frame: Baseline, weekly during the 8-week intervention, and at 2-, 6-, and 12-months post intervention

07

Study locations

1 site
  • Room 124007, 10/F, Lui Chi Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07117929
Lead sponsor
Chinese University of Hong Kong
Responsible party
Patrick Shu-Hang YUNG (Professor and Chairman, Department of Orthopaedics & Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Chinese University of Hong Kong) — Principal investigator
First posted
Aug 12, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 12, 2025

Study contacts

Josephine Lai
Contact
wingheilai@cuhk.edu.hk
(852)26364171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion